{"entity":{"type":"insider","cik":"0001690298","url":"/insider/0001690298","json_url":"/insider/0001690298.json","name":"Curran Terrie","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":18,"n_filings":15,"first":"2017-09-26","last":"2026-08-24","span_basis":"filed_date"},"name_variants":[{"name":"Curran Terrie","source":"filing","n_filings":15,"first_seen":"2017-09-26","last_seen":"2026-08-24"}],"transactions":[{"id":9300900,"accession":"0001628280-26-058648","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-058648","line_url":"/filing/0001628280-26-058648#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1072.0,"shares_display":"1,072","price_per_share":26.0376,"price_display":"26.04","price_state":"stated","total_value":27912.3072,"total_display":"27,912.31","total_whole":"27,912","shares_owned_after":23526.0,"shares_owned_after_display":"23,526","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-20","filed_date":"2026-08-24","scope":"insider"},{"id":5195964,"accession":"0000950170-25-008348","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-008348","line_url":"/filing/0000950170-25-008348#line-1","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19109.0,"shares_display":"19,109","price_per_share":6.5877,"price_display":"6.59","price_state":"stated","total_value":125884.3593,"total_display":"125,884.36","total_whole":"125,884","shares_owned_after":360465.0,"shares_owned_after_display":"360,465","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-21","filed_date":"2025-01-23","scope":"insider"},{"id":2664366,"accession":"0001787306-24-000155","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-24-000155","line_url":"/filing/0001787306-24-000155#line-1","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8687.0,"shares_display":"8,687","price_per_share":10.8482,"price_display":"10.85","price_state":"stated","total_value":94238.3134,"total_display":"94,238.31","total_whole":"94,238","shares_owned_after":10139.0,"shares_owned_after_display":"10,139","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-11","filed_date":"2024-11-13","scope":"insider"},{"id":2205792,"accession":"0000950170-24-084179","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-084179","line_url":"/filing/0000950170-24-084179#line-1","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33848.0,"shares_display":"33,848","price_per_share":11.72,"price_display":"11.72","price_state":"stated","total_value":396698.56,"total_display":"396,698.56","total_whole":"396,699","shares_owned_after":377734.0,"shares_owned_after_display":"377,734","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-15","filed_date":"2024-07-17","scope":"insider"},{"id":3214230,"accession":"0000950170-24-036398","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-036398","line_url":"/filing/0000950170-24-036398#line-1","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16851.0,"shares_display":"16,851","price_per_share":9.11,"price_display":"9.11","price_state":"stated","total_value":153512.61,"total_display":"153,512.61","total_whole":"153,513","shares_owned_after":410784.0,"shares_owned_after_display":"410,784","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-22","filed_date":"2024-03-26","scope":"insider"},{"id":8744835,"accession":"0001209191-23-023751","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-023751","line_url":"/filing/0001209191-23-023751#line-1","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12919.0,"shares_display":"12,919","price_per_share":7.8199,"price_display":"7.82","price_state":"stated","total_value":101025.2881,"total_display":"101,025.29","total_whole":"101,025","shares_owned_after":188290.0,"shares_owned_after_display":"188,290","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-06","filed_date":"2023-04-07","scope":"insider"},{"id":8152297,"accession":"0001209191-23-016002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-016002","line_url":"/filing/0001209191-23-016002#line-1","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1436.0,"shares_display":"1,436","price_per_share":8.5411,"price_display":"8.54","price_state":"stated","total_value":12265.0196,"total_display":"12,265.02","total_whole":"12,265","shares_owned_after":175371.0,"shares_owned_after_display":"175,371","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider"},{"id":8214258,"accession":"0001209191-23-004341","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-004341","line_url":"/filing/0001209191-23-004341#line-2","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5821.0,"shares_display":"5,821","price_per_share":8.1995,"price_display":"8.20","price_state":"stated","total_value":47729.2895,"total_display":"47,729.29","total_whole":"47,729","shares_owned_after":176807.0,"shares_owned_after_display":"176,807","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-20","filed_date":"2023-01-20","scope":"insider"},{"id":6632513,"accession":"0001209191-22-058619","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-058619","line_url":"/filing/0001209191-22-058619#line-1","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1526.0,"shares_display":"1,526","price_per_share":9.6,"price_display":"9.60","price_state":"stated","total_value":14649.6,"total_display":"14,649.60","total_whole":"14,650","shares_owned_after":83720.0,"shares_owned_after_display":"83,720","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-21","filed_date":"2022-11-23","scope":"insider"},{"id":6210285,"accession":"0001209191-22-029451","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-029451","line_url":"/filing/0001209191-22-029451#line-1","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20500.0,"shares_display":"20,500","price_per_share":7.4066,"price_display":"7.41","price_state":"stated","total_value":151835.3,"total_display":"151,835.30","total_whole":"151,835","shares_owned_after":64595.0,"shares_owned_after_display":"64,595","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-13","filed_date":"2022-05-16","scope":"insider"},{"id":4628805,"accession":"0001209191-21-055667","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-055667","line_url":"/filing/0001209191-21-055667#line-2","is_derivative":false,"issuer_cik":"0001679082","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001679082","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4850.0,"shares_display":"4,850","price_per_share":25.58,"price_display":"25.58","price_state":"stated","total_value":124063.0,"total_display":"124,063.00","total_whole":"124,063","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-09","filed_date":"2021-09-13","scope":"insider"},{"id":4896394,"accession":"0001209191-21-054758","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-054758","line_url":"/filing/0001209191-21-054758#line-4","is_derivative":false,"issuer_cik":"0001679082","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001679082","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37135.0,"shares_display":"37,135","price_per_share":25.03,"price_display":"25.03","price_state":"stated","total_value":929489.05,"total_display":"929,489.05","total_whole":"929,489","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-02","filed_date":"2021-09-03","scope":"insider"},{"id":4896386,"accession":"0001209191-21-054758","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-054758","line_url":"/filing/0001209191-21-054758#line-2","is_derivative":false,"issuer_cik":"0001679082","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001679082","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11373.0,"shares_display":"11,373","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":284325.0,"total_display":"284,325.00","total_whole":"284,325","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-01","filed_date":"2021-09-03","scope":"insider"},{"id":4885301,"accession":"0001209191-21-022705","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-022705","line_url":"/filing/0001209191-21-022705","is_derivative":false,"issuer_cik":"0001690298","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001690298","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11513.0,"shares_display":"11,513","price_per_share":43.320668670198906,"price_display":"43.32","price_state":"stated","total_value":498750.8584,"total_display":"498,750.86","total_whole":"498,751","shares_owned_after":1140.0,"shares_owned_after_display":"1,140","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-22","filed_date":"2021-03-23","scope":"insider","n_lines":2},{"id":7852531,"accession":"0001415889-19-001066","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-19-001066","line_url":"/filing/0001415889-19-001066","is_derivative":false,"issuer_cik":"0000816284","issuer_name":"CELGENE CORP /DE/","issuer_ticker":"CELG","issuer_name_source":null,"issuer_url":"/issuer/0000816284","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Officer","role_mark":"O","role_mark_label":"Officer","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SEE REMARKS","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11338.0,"shares_display":"11,338","price_per_share":98.26634150643852,"price_display":"98.27","price_state":"stated","total_value":1114143.78,"total_display":"1,114,143.78","total_whole":"1,114,144","shares_owned_after":2155.0,"shares_owned_after_display":"2,155","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-18","filed_date":"2019-09-19","scope":"insider","n_lines":2},{"id":5071676,"accession":"0001209191-17-053976","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-053976","line_url":"/filing/0001209191-17-053976#line-1","is_derivative":false,"issuer_cik":"0000816284","issuer_name":"CELGENE CORP /DE/","issuer_ticker":"CELG","issuer_name_source":null,"issuer_url":"/issuer/0000816284","owner_cik":"0001690298","owner_name":"Curran Terrie","owner_display_name":"Curran Terrie","owner_url":"/insider/0001690298","role":"Officer","role_mark":"O","role_mark_label":"Officer","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1727.0,"shares_display":"1,727","price_per_share":143.89,"price_display":"143.89","price_state":"stated","total_value":248498.03,"total_display":"248,498.03","total_whole":"248,498","shares_owned_after":3925.0,"shares_owned_after_display":"3,925","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-25","filed_date":"2017-09-26","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":18,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":16,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":18},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001787306","name":"Arcutis Biotherapeutics, Inc.","url":"/issuer/0001787306","role":"Director","n_filings":2,"first_seen":"2024-11-13","last_seen":"2026-08-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001783183","name":"Phathom Pharmaceuticals, Inc.","url":"/issuer/0001783183","role":"Director, Officer (President and Chief Executive)","n_filings":9,"first_seen":"2021-03-23","last_seen":"2025-01-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001679082","name":"Myovant Sciences Ltd.","url":"/issuer/0001679082","role":"Director","n_filings":2,"first_seen":"2021-09-03","last_seen":"2021-09-13"},{"type":"issuer","type_label":"ISSUER","cik":"0000816284","name":"CELGENE CORP /DE/","url":"/issuer/0000816284","role":"Officer","n_filings":2,"first_seen":"2017-09-26","last_seen":"2019-09-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001690298","retrieved_at":"2026-08-25T08:57:11+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}